The conference, among the more prestigious for investors in healthcare companies, is sponsored by Barron's, The Wall Street Journal and Business Wire. It is held at The Hyatt Regency Hotel, 5 Embarcadero Center, San Francisco.

Investors interested in attending the conference need to pre-register by contacting Cary Loeser at cloeser@wilink.com or by calling 804/327-3407. The presentation is available on the Internet by registering at the following link: http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp. Questions about the conference or Internet registration will be answered at Customer Service at 888/301-6618. The event will be archived and available via webcast at http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp.

"We are continuously involved in telling our exciting story to investor groups and we are looking forward to explaining to this group how cord blood stem cell storage is the best possible insurance policy that a family can give to itself," Mr. Schissler said.

This press release is available on the Cord Blood America IR HUB for investor commentary, feedback and questions. Investors are asked to visit http://www.agoracom.com/IR/CordBloodAmerica. Alternatively, investors are asked to e-mail all questions and correspondence to CBAI@agoracom.com where they can also request addition to the investor e-mail list to receive all future press releases and correspondence directly.

About Cord Blood America

Cord Blood America (OTCBB:CBAI) is the parent company of Cord Partners, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. For more information on how this precious lifeline can benefit your family, visit http://www.cordpartners.com. For investor information, visit www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as ``anticipate,'' ``believe,'' ``expect,'' ``future,'' ``intend,'' ``plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The company's past performance is not necessarily indicative of its future performance. The company does not undertake, and the company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.